Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF: Endostar and Low-dose CCRT Followed by Durvalumab in Stage III NSCLC
NCT04613284Phase 4Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2020
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 4, open-label, single-arm trial of endostar and durvalumab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoints: Progression Free Survival at 3 years and Adverse Events at 5 years. Status: unknown.
02
Drugs
endostardurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04613284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613284.